摘要
胶质瘤是神经外科最常见的恶性肿瘤,临床尚缺乏有效的治疗手段。肿瘤干细胞被认为是胶质瘤发生、发展的源头而受到越来越多的关注。干细胞标志物CD133广泛表达于人体多种肿瘤中,同时,它也是研究得最多且应用最广的胶质瘤干细胞表面标志物。然而,利用CD133进行胶质瘤干细胞的鉴定和筛选正逐渐受到质疑。本文将对近年来人们发现的CD133作为胶质瘤干细胞标志物应用的局限性进行综述。
Glioma is the most common type of primary malignant brain tumors,which lacks of effective clinical treatment.Tumor stem cells are considered to be the source of human glioma development and are getting more and more attention.Stem cell marker CD133 is widely expressed in many human tumors,meanwhile,it is also the most studied and widely used glioma stem cell surface marker.However,the amplication of CD133 in glioma stem cells identification and screening is questioned.In this review,we summarized the limitations of CD133 in recent glioma stem cells research.
出处
《中国神经肿瘤杂志》
2010年第2期129-134,共6页
Chinese Journal of Neuro-Oncology
基金
国家自然科学基金资助项目(No.30801177)
